This trial will help determine if a correlation exists between how a tumor looks on a DT PET scan and how aggressive it is.
2 Primary · 3 Secondary · Reporting Duration: 2 years
0 Treatment Group
40 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there an opportunity for individuals to join the experiment?
"Based on the information provided by clinicaltrials.gov, this study is still enrolling patients as of May 20th 2022. The trial was initially launched in March 4th 2021." - Anonymous Online Contributor
What other investigations have been conducted surrounding this therapy?
"Currently, 18 studies are being conducted in relation to this treatment. One is at the pivotal Phase 3 stage and 19 different sites across Wuhan, Hubei province are running tests on it." - Anonymous Online Contributor
What conditions can this particular remedy ameliorate?
"This pharmaceutical is typically used to manage seizures, but it has also been demonstrated as a viable option for treating coronary artery disease (CAD), cancer, and positron emission tomography." - Anonymous Online Contributor
What is the current enrollment of this clinical research endeavor?
"Affirmative. According to clinicaltrials.gov, this research is actively enrolling participants; it was first published on March 4th 2021 and the most recent update occurred on May 20th 2022. The study requires 40 individuals from one medical site." - Anonymous Online Contributor